Literature DB >> 26713408

Enhanced Tyrosine Phosphatase Activity Underlies Dysregulated B Cell Receptor Signaling and Promotes Survival of Human Lupus B Cells.

Sarah J Fleischer1, Capucine Daridon1, Vanessa Fleischer1, Peter E Lipsky2, Thomas Dörner1.   

Abstract

OBJECTIVE: Systemic lupus erythematosus (SLE) is associated with hyperactivity of B cells and abnormalities of B cell receptor (BCR) signaling. To address the linkage between dysregulated BCR signaling and increased B cell function, we assessed immediate phosphorylation events in lupus B cells.
METHODS: B cells from SLE patients and healthy donors were analyzed by flow cytometry to assess phosphorylated CD22, Syk, and Akt as well as the basal expression of the BCR coreceptors CD22 and CD19. Confocal microscopy studies determined the recruitment of CD22 and the tyrosine phosphatase SH2 domain-containing phosphatase 1 to the activated BCR complex. Additionally, phosphatase activity in SLE versus healthy donor B cells was measured.
RESULTS: B cells from SLE patients showed diminished Syk phosphorylation and reduced intracellular calcium release after BCR activation as compared to B cells from healthy donors. This was related to an enhanced activity of tyrosine, but not serine/threonine, phosphatases and was corrected by inhibition of tyrosine phosphatase activity. In contrast to reduced Syk phosphorylation after BCR activation, phosphorylation of Akt was significantly increased in SLE B cells. The disturbed balance between Syk and Akt phosphorylation was significantly correlated with B cell survival following BCR engagement. Furthermore, CD27-, but not CD27+, B cells from SLE patients displayed increased expression and phosphorylation of the inhibitory BCR coreceptor CD22.
CONCLUSION: These results indicate that an imbalance between serine and tyrosine phosphatases in SLE contributes to an intrinsically disturbed balance of BCR-initiated signaling pathways, resulting in enhanced survival of lupus B cells and differentiation into plasma cells.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26713408     DOI: 10.1002/art.39559

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  15 in total

Review 1.  Calcium Signaling: From Normal B Cell Development to Tolerance Breakdown and Autoimmunity.

Authors:  Patrice Hemon; Yves Renaudineau; Marjolaine Debant; Nelig Le Goux; Sreya Mukherjee; Wesley Brooks; Olivier Mignen
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

Review 2.  Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.

Authors:  Thomas Dörner; Peter E Lipsky
Journal:  Nat Rev Rheumatol       Date:  2016-10-13       Impact factor: 20.543

3.  Age-associated B Cells Appear in Patients with Granulomatous Lung Diseases.

Authors:  Swati Phalke; Katja Aviszus; Kira Rubtsova; Anatoly Rubtsov; Briana Barkes; Linda Powers; Brenda Warner; James L Crooks; John W Kappler; Evans R Fernández-Pérez; Lisa A Maier; Nabeel Hamzeh; Philippa Marrack
Journal:  Am J Respir Crit Care Med       Date:  2020-10-01       Impact factor: 21.405

Review 4.  Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives.

Authors:  Eva Schrezenmeier; David Jayne; Thomas Dörner
Journal:  J Am Soc Nephrol       Date:  2018-01-11       Impact factor: 10.121

5.  Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor.

Authors:  Simon Lumb; Sarah J Fleischer; Annika Wiedemann; Capucine Daridon; Alison Maloney; Anthony Shock; Thomas Dörner
Journal:  J Cell Commun Signal       Date:  2016-04-28       Impact factor: 5.782

6.  BTLA Expression and Function Are Impaired on SLE B Cells.

Authors:  Annika Wiedemann; Marie Lettau; Sarah Y Weißenberg; Ana-Luisa Stefanski; Eva-Vanessa Schrezenmeier; Hector Rincon-Arevalo; Karin Reiter; Tobias Alexander; Falk Hiepe; Andreia C Lino; Thomas Dörner
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

7.  Interferon α Enhances B Cell Activation Associated With FOXM1 Induction: Potential Novel Therapeutic Strategy for Targeting the Plasmablasts of Systemic Lupus Erythematosus.

Authors:  Kanae Akita; Ken Yasaka; Tsuyoshi Shirai; Tomonori Ishii; Hideo Harigae; Hiroshi Fujii
Journal:  Front Immunol       Date:  2021-02-03       Impact factor: 7.561

8.  Transgelin-2 is upregulated on activated B-cells and expressed in hyperplastic follicles in lupus erythematosus patients.

Authors:  Kaori Kiso; Hajime Yoshifuji; Takuma Oku; Masaki Hikida; Koji Kitagori; Yoshitaka Hirayama; Toshiki Nakajima; Hironori Haga; Tatsuaki Tsuruyama; Aya Miyagawa-Hayashino
Journal:  PLoS One       Date:  2017-09-14       Impact factor: 3.240

9.  Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling.

Authors:  Natalia V Giltiay; Geraldine L Shu; Anthony Shock; Edward A Clark
Journal:  Arthritis Res Ther       Date:  2017-05-15       Impact factor: 5.156

10.  CD47 Potentiates Inflammatory Response in Systemic Lupus Erythematosus.

Authors:  Jin Kyun Park; Ye Ji Lee; Ji Soo Park; Eun Bong Lee; Yeong Wook Song
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.